Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8551172 | Regulatory Toxicology and Pharmacology | 2018 | 6 Pages |
Abstract
Vitacoxib, a selective COX-2 inhibitor, is approved for the relief of pain and inflammation associated with orthopedic surgery and osteoarthritis in dogs. In the current study, a chronic toxicity research was performed to evaluate the safety of vitacoxib in male and female rats for long-term. Vitacoxib was dosed orally to groups of rats for 180 days at 1.2, 6, 30â¯mg/kgâ¯bw/day by gavage. The chronic study oral administration of vitacoxib did not show observational or toxicological effects on the body or organ weights, food consumption, hematology and biochemistry at dose 6â¯mg/kg bw. However, vitacoxib (30â¯mg/kg) showed minor alterations to histopathology of liver, kidney and stomach related to treatment. These results provide further indication that vitacoxib is safe and well-tolerated in rats after 180 days of daily oral administration at 6â¯mg/kg bw and the NOAEL for both sexes was 6â¯mg/kg bw for 180 consecutive days.
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Jianzhong Wang, Tingting Zhao, Shusheng Tang, Suxia Zhang, Pengyyue Lv, Jing Li, Xingyuan Cao,